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Abstract
Receptor tyrosine kinases such as the epidermal growth
factor receptor (EGFR) play an important role in a
variety of malignant neoplasias, making the search for
aberrations in the relevant chromosomes an important
issue. Differential expression of the EGFR gene was
investigated by reverse transcriptase (RT)-PCR on
tissue samples of normal skin, nevi, primary melano-
mas, and melanoma metastases. The EGFR gene is
located on chromosome 7p12.3-p12.1. To determine the
number of chromosomes 7 in cell nuclei of the
mentioned tissue samples we performed fluorescence
in situ hybridization (FISH) on touch preparations,
using a DNA probe that hybridizes specifically to the
centromeric region of chromosome 7. Additionally,
chromosome 7 number in interphase nuclei was deter-
mined in short - term primary cell cultures of nevi,
primary melanomas, and metastases. The highest EGFR
gene expression frequency was found in melanoma
metastases. By FISH we detected the highest fraction of
cell nuclei with more than two chromosomes 7 in the
group of metastases. Our results suggest that over-
expression of the EGFR gene might play an important
role in metastasis of malignant melanoma. This is well
reflected by polysomy 7, possibly accounting for an
increased EGFR gene copy number. Neoplasia (2001) 3,
245–254.
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Introduction
Despite the rising incidence rates and the potentially lethal
outcome of malignant melanoma, little is known on the
pathogenetic mechanisms causing this cutaneous neo-
plasia. Of special interest are the supposedly consecutive
steps from a benign melanocytic nevus to the malignant
melanoma and the formation of metastases. As has been
shown for numerous malignancies, this malignant trans-
formation is often associated with structural or numerical
cytogenetic aberrations [1]. In human malignant mela-
noma, numerical and structural abnormalities of chromo-
somes 1, 3, 6, 9, 10, 11, and 17 were the most frequently
described [2–13].
In recent years a plethora of proto-oncogenes, onco-
genes, and tumor suppressor genes have been investigated
in malignant melanoma to identify causative genetic alter-
ations. Among these, receptor tyrosine kinases (RTKs) have
emerged as a highly interesting group of cell membrane–
bound receptors involved in signal transduction processes.
There is compelling evidence supporting the involvement of
RTKs in human carcinogenesis [14–19]. RTKs are regu-
latory transmembrane proteins that transmit biological
signals from the extracellular environment to the interior cell
departments. This signal transduction system has been
implicated to regulate cellular functions such as cell
proliferation or differentiation [20]. Epidermal growth factor
receptor (EGFR), first studied in the epidermoid carcinoma
cell line A431 [21], was shown to contribute to or cause
malignant cell transformation in gastrointestinal, urinary, and
reproductive tract malignancies, brain tumors, lung carci-
noma [22], cutaneous squamous cell carcinomas, and
melanomas [23]. Although mutations of RTKs as pathoge-
netic factors for malignant transformation, such as the
mutated EGFR in human gliomas [24,25], have been
reported, the prevalent RTK-related defect appears to be
abnormal overexpression caused by amplification or
impaired control of gene expression.
Due to controversial results and the lack of expression
studies on the RNA level in melanoma and nevus tissue, we
performed comparative EGFR expression analysis in normal
skin, nevi, primary melanoma, and melanoma metastases.
The EGFR gene is located on chromosome 7p12.3-p12.1.
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As altered gene expression can be due to gene dosage
effects resulting from either more or less than the usual two
gene copies per nucleus, we examined the abovementioned
tissue types for the copy number of chromosome 7 by
fluorescence in situ hybridization (FISH). FISH enables the
detection of numerical and structural chromosomal aberra-
tions in both interphase cell nuclei and metaphase spreads.
For enumeration of chromosome copy numbers, chromo-
some specific centromeric DNA probes can be used. As
FISH on thin tissue sections faces the problem that signals
could be missed due to only one single section plane, we
performed FISH on cell nuclei derived from touch prepara-
tions of fresh tumor tissue and on nuclei derived from short -
term primary cell cultures.
Material and Methods
Clinical Material
Fresh tissue samples were obtained from patients, frozen
in liquid nitrogen immediately after excision, and stored at
808C until preparation for interphase FISH or RNA. For
FISH we obtained tissues from 8 melanocytic nevi, 18
primary cutaneous malignant melanomas [ including super-
ficial spreading melanomas (SSM, n=7), lentigo malignant
melanomas (LMM, n=2), nodular malignant melanomas
(NMM, n=5), and unclassified melanomas (MM, n=4) ], and
41 cutaneous and lymph node metastases. Seven control
samples were obtained from normal, non-neoplastic tissue
and safety margins. All diagnoses had been confirmed
histologically.
Additionally, we established short - term primary cell
cultures of nevi, primary melanomas, and melanoma
metastases. We examined primary cultures from two nevi,
one primary malignant melanoma, and three melanoma
metastases by interphase FISH.
For reverse transcriptase (RT)-PCR analysis of EGFR
gene expression we investigated tissue specimens taken
from normal skin (n=16), nevi (n=28), primary malignant
melanomas (n=47), and melanoma metastases (n=14).
Eight of the 16 samples from normal skin had been
excised from non–UV-exposed gluteal skin to avoid
alterations of gene expression levels by ultraviolet radia-
tion. Primary melanomas consisted of 19 NMMs, 22 SSMs,
2 LMMs, 2 acrolentiginous melanomas (ALM) and 2
melanomas on nevus. Additionally, 2 locoregional cuta-
neous melanoma metastases and 12 distant cutaneous
and lymph node metastases were studied. Tumor thick-
ness of primary melanomas ranged from 0.2 to 12.1 mm.
Mean tumor thickness for SSM was 0.86 mm, for NMM
3.17 mm. 30 melanoma patients were female, 33 were
male Caucasians.
Fluorescence in Situ Hybridization (FISH)
Primary cell cultures sample preparation Fresh cutaneous
tissue was minced finely, pieces were resuspended several
times to separate single cells from tissue pieces and
suspension was seeded in cell culture flasks. Culture media
were DMEM (Gibco, Karlsruhe, Germany) containing 10%
FCS (Biochrom, Berlin, Germany) or Ham’s F12 (Gibco)
modified with 17% FCS (Biochrom), 3% horse serum
(Biochrom), Choleratoxin (83.2 ng/ml; Sigma, Deisenhofen,
Germany), and PMA (10 ng/ml; Boehringer Ingelheim,
Heidelberg, Germany). Cells were cultured at 378C and 4%
or 8.5% CO2 using Ham’s F12 or DMEM, respectively. At
time of harvesting cells were trypsinized, incubated in
hypotonic KCl (75 mM), fixed in Carnoy’s solution (3:1
methanol:acetic acid), and dropped on methanol -cleaned
slides. In situ hybridization was performed as described
elsewhere [26]. For a brief description cf. Fluorescence In
Situ Hybridization section.
Touch preparations We performed touch preparations of
tissue specimens by gently touching the not fully thawed
sample to the surface of a positive loaded slide. The slides
were air -dried for 5 to 7 hours before fixing in 4%
paraformaldehyde/1PBS for 20 minutes. Slides were
washed in 3PBS and 1PBS (twice) 5 minutes each,
dehydrated by incubation in ethanol (30%, 60%, 80%, 95%,
100%) and air -dried. After incubation of the slides on a
heating block at 558C overnight, RNase digestion (100 g/
ml) was performed for 1 hour at 378C in a humid chamber.
Afterwards, touch preparations were incubated in 2SSC at
758C for 15 minutes. The slides were digested in pepsin
solution (4 mg/ml in 0.9% NaCl, pH 1.5) for 15 minutes at
378C. This reaction was stopped by washing with 2SSC for
5 minutes. Slides were then air -dried.
Fluorescence in situ hybridization The method of inter-
phase FISH was performed as described elsewhere [26].
In brief, we used a directly fluorescent- labeled,  -satellite
DNA probe ( labeled with spectrum orange; VYSIS,
Downers Grove, IL) that hybridizes to the centromere
region of human chromosome 7. The probe was mixed
according to the manufacturer’s description and applied
on the slide preparations. Probe and target DNA were
denatured simultaneously in a 788C oven for 4 minutes
and then hybridized at 428C overnight in a humid
chamber. Posthybridization washes were performed in
1.5 M urea/0.1SSC at 458C for 30 minutes and in
2SSC at room temperature for 2 minutes. Finally, nuclei
were counterstained with DAPI (40,6 -diamidino-2-phenyl-
indole) in antifade compound (containing p -phenylenedi-
amine).
Analysis of interphase FISH Fluorescence signals in 100
interphase nuclei were scored per sample using a fluores-
cence microscope (Zeiss, Germany) equipped with light
filters for different wavelengths and a digital camera
connected to a computer with MacProbe software (PSI,
England) for analysis. Counting of signals was performed
applying the following criteria: (a) fluorescent signals were
scored as true hybridization events only if they were
approximately the same size and intensity as those in
adjacent cells, (b) paired signals were scored as single
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Table 1. FISH Signals per Nucleus for Chromosome 7 in Samples of Different Tissue Types.
Diagnosis Case no. Signals per nucleus (%)
0 1 2 3 4 5 6 7 8 >5
Controls
Muscle 249 3.0 9.0 81.0 4.0 1.0 0.0 ND 2.0
Normal skin 235 0.0 4.0 91.0 4.0 1.0 0.0 0.0 0.0
Mucous membrane 233 3.8 6.7 83.7 4.8 1.0 0.0 0.0 0.0
Unaffected tissue 305 3.0 13.0 81.0 3.0 0.0 0.0 0.0 0.0
Unaffected tissue 312 0.0 13.0 83.0 4.0 0.0 0.0 0.0 0.0
Safety margin 310 1.0 7.0 89.0 2.0 1.0 0.0 0.0 0.0
Safety margin 480 2.0 23.0 73.0 2.0 0.0 0.0 0.0 0.0
Mean value 1.8 10.8 83.1 3.4 0.6 0.0 0.0 0.3
Standard deviation 1.4 5.8 5.5 1.0 0.5 0.0 0.0 0.7
Nevi
Nevus giganteus 199 0.0 10.8 82.4 6.9 0.0 0.0 0.0 0.0
NCN 302 4.0 19.0 75.0 2.0 0.0 0.0 0.0 0.0
NCN 303 1.0 12.9 81.2 3.0 2.0 0.0 0.0 0.0
NCN 304 1.0 12.0 77.0 7.0 2.0 0.0 1.0 1.0
NCN 306 0.0 7.0 87.0 3.0 3.0 0.0 0.0 0.0
NCN 309 1.0 7.0 91.0 1.0 0.0 0.0 0.0 0.0
NCN 366 3.0 13.0 80.0 4.0 0.0 0.0 0.0 0.0
NCN 367 3.0 9.0 85.0 3.0 0.0 0.0 0.0 0.0
Mean value 1.6 11.3 82.3 3.7 0.9 0.0 0.1 0.1
Standard deviation 1.4 3.7 4.9 2.0 1.2 0.0 0.3 0.3
Primary melanomas
LMM 289 0.0 11.8 82.4 4.9 1.0 0.0 0.0 0.0
LMM 295 1.0 2.0 25.0 13.0 22.0 19.0 17.0 1.0 18.0
MM 210 0.0 8.8 49.0 32.4 6.9 ND ND 2.9
MM 268 2.0 6.0 77.0 6.0 8.0 0.0 1.0 1.0
MM 308 2.0 4.0 91.0 2.0 1.0 0.0 0.0 0.0
MM 363 0.0 1.0 77.0 12.0 5.0 4.0 1.0 1.0
NMM 209 0.0 16.4 76.2 6.6 0.8 0.0 0.0 0.0
NMM 267 0.0 4.0 70.0 10.0 1.0 6.0 9.0 9.0
NMM 290 1.0 17.0 79.0 2.0 1.0 0.0 0.0 0.0
NMM 291 0.9 16.8 76.6 5.6 0.0 0.0 0.0 0.0
NMM 293 2.0 5.0 84.0 7.0 1.0 1.0 0.0 0.0
SSM 211 0.0 7.7 81.7 7.7 1.9 0.0 0.0 1.0
SSM 236 2.0 13.0 70.0 8.0 4.0 0.0 0.0 3.0
SSM 250 0.0 5.0 83.0 7.0 5.0 0.0 0.0 0.0
SSM 307 2.0 10.0 78.0 6.0 4.0 0.0 0.0 0.0
SSM 315 1.0 5.0 89.0 4.0 1.0 0.0 0.0 0.0
SSM 352 1.0 11.0 80.0 6.0 1.0 1.0 0.0 0.0
SSM 474 1.0 10.0 81.0 8.0 0.0 0.0 0.0 0.0
Mean value 0.9 8.6 75.0 8.2 3.6 1.8 1.6 2.0
Standard deviation 0.8 4.9 14.9 6.5 5.0 4.6 4.4 4.4
Metastases
Mel.Met. 195 0.0 8.0 62.0 27.0 3.0 0.0 0.0 0.0
Mel.Met. 205 0.0 10.9 76.2 12.9 0.0 0.0 0.0 0.0
Mel.Met. 206 0.0 18.8 75.0 3.8 2.5 0.0 0.0 0.0
Mel.Met. 208 0.0 13.9 72.3 8.9 5.0 0.0 0.0 0.0
Mel.Met. 218 2.0 8.0 80.0 8.0 2.0 0.0 0.0 0.0
Mel.Met. 234 0.0 4.7 68.0 26.0 0.7 0.0 0.0 0.7
Mel.Met. 265 1.0 0.0 33.0 14.0 21.0 27.0 4.0 4.0
Mel.Met. 266 0.0 1.0 15.0 7.0 28.0 44.0 5.0 5.0
Mel.Met. 292 1.0 2.0 16.0 18.0 21.0 19.0 21.0 2.0 23.0
Mel.Met. 294 1.0 7.0 88.0 2.0 1.0 1.0 0.0 0.0
Mel.Met. 311 0.0 4.0 39.0 36.0 20.0 1.0 0.0 0.0
Mel.Met. 313 0.0 8.0 63.0 15.0 12.0 2.0 0.0 0.0
(continued on next page)
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events, and (c) only signals in nonoverlapping, apparently
intact nuclei were scored.
Statistical analysis Statistical analysis comparing the dis-
tributions of the mean fraction of nuclei with a certain number
of FISH signals in primary melanomas and melanoma
metastases was performed using the two-sided Kolmo-
gorov-Smirnov exact test. The differences were considered
to be statistically significant if the P value was .025 or less.
RT-PCR Analysis of EGFR Gene Expression
RNA isolation A total of 105 tissue samples from patients
with melanocytic nevi, cutaneous malignant melanomas,
metastases, and normal skin were investigated. At time of
preparation the tissue was minced and total mRNAs were
isolated from homogenates using the RNA-Clean System
(Angewandte Gentechnologie Systeme, Germany).
Reverse transcription Using oligo (dt ) primers the extracted
mRNA was reverse transcribed with the Reverse Tran-
scriptase System (Promega, Madison, WI). The obtained
cDNAs were then phenol /chloroform extracted, precipitated
by ethanol extraction and redissolved in double-distilled
H2O. The cDNA concentration was measured by light
absorbance at 260 nm.
PCR In PCR reactions (25 l ) 100 ng cDNA template was
used to analyze expression of the EGFR gene. Besides, the
PCR mixtures contained 1.5 mM MgCl2, 0.2 mM dNTPs
(Promega), 0.2 l Taq polymerase (5 U/l, Boehringer
Mannheim, Germany) and 1 M sense and antisense
primers: 50 -ACT AGC CAG GAA GTA CTT CC-30 and 50 -
GGC CTT CTT GGA TCT TTA GT-30. Cycling parameters:
an initial heating step (948C, 4 minutes), followed by 938C,
35 seconds; 608C, 35 seconds; 728C, 35 seconds; 35 cycles,
and one final extension step (688C, 10 minutes); predicted
product size: 398 bp.
It was tested that PCRwas still in the exponential phase at
the end of cycling. To circumvent false-negative results we
used primers detecting expression of the housekeeping
gene GAPDH (Glyceraldehyde-3-phosphate Dehydrogen-
ase). Genomic contamination was ruled out by the use of a
Table 1. (continued).
Diagnosis Case no. Signals per nucleus (%)
0 1 2 3 4 5 6 7 8 >5
Mel.Met. 314 0.0 7.0 51.0 34.0 7.0 1.0 0.0 0.0
Mel.Met. 337 0.0 11.0 55.0 34.0 0.0 0.0 0.0 0.0
Mel.Met. 338 0.0 2.0 17.0 8.0 25.0 35.0 12.0 1.0 13.0
Mel.Met. 339 0.0 7.0 47.0 14.0 30.0 1.0 0.0 1.0 1.0
Mel.Met. 340 0.0 2.0 21.0 73.0 3.0 0.0 1.0 1.0
Mel.Met. 348 2.0 14.8 72.1 9.8 0.0 0.0 0.0 0.0
Mel.Met. 349 0.0 13.8 48.3 24.1 13.8 0.0 0.0 0.0
Mel.Met. 350 1.0 8.9 54.5 25.7 8.9 1.0 0.0 0.0
Mel.Met. 351 1.0 13.9 53.5 10.9 5.0 9.9 5.0 1.0 6.0
Mel.Met. 355 0.0 1.0 49.0 48.0 2.0 0.0 0.0 0.0
Mel.Met. 364 1.0 5.0 66.0 17.0 3.0 2.0 6.0 6.0
Mel.Met. 365 1.0 10.0 46.0 39.0 1.0 1.0 2.0 2.0
Mel.Met. 369 0.0 5.0 84.0 5.0 3.0 3.0 0.0 0.0
Mel.Met. 370 1.0 3.0 27.0 69.0 0.0 0.0 0.0 0.0
Mel.Met. 415 0.0 5.0 54.0 39.0 2.0 0.0 0.0 0.0
Mel.Met. 416 0.0 0.0 16.0 7.0 11.0 40.0 22.0 26.0
Mel.Met. 417 0.0 0.9 34.0 53.8 9.4 1.9 0.0 0.0
Mel.Met. 418 1.0 13.0 82.0 2.0 2.0 0.0 0.0 0.0
Mel.Met. 420 0.0 1.0 9.0 47.0 40.0 2.0 0.0 1.0 1.0
Mel.Met. 421 1.0 7.0 40.0 49.0 3.0 0.0 0.0 0.0
Mel.Met. 422 0.0 2.0 29.0 52.0 13.0 1.0 2.0 1.0 3.0
Mel.Met. 423 1.0 8.0 74.0 5.0 2.0 5.0 3.0 2.0 5.0
Mel.Met. 425 0.0 4.0 22.0 7.0 16.0 37.0 11.0 3.0 14.0
Mel.Met. 470 0.0 4.4 75.0 15.2 2.2 2.2 1.1 1.1
Mel.Met. 471 1.0 8.0 88.0 3.0 0.0 0.0 0.0 0.0
Mel.Met. 473 0.0 2.9 57.4 35.3 1.5 1.5 1.5 1.5
Mel.Met. 475 0.0 2.0 11.0 86.0 1.0 0.0 0.0 0.0
Mel.Met. 477 0.0 5.0 84.0 8.0 3.0 0.0 0.0 0.0
Mel.Met. 481 0.0 8.0 50.0 37.0 4.0 0.0 1.0 1.0
Mean value 0.4 6.4 51.3 25.3 8.0 5.8 2.4 2.8
Standard deviation 0.6 4.6 23.6 21.0 9.7 12.1 5.1 5.9
NCN, nevus cell nevus. LMM, lentigo malignant melanoma. NMM, nodular malignant melanoma. SSM, superficial spreading melanoma.MM, malignant melanoma
(unclassified ). Mel.Met., melanoma metastasis. ND: not determined.
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further intron-spanning set of primers with different product
sizes for genomic DNA and cDNA. As a positive control
cDNA prepared from the melanoma cell line C32 (CRL-
1585, ATCC, Rockville, MD) was amplified. Water instead of
cDNA template was applied as a negative control. In parallel,
100 ng of genomic DNA was amplified. The PCR-band
intensity of genomic DNA was determined as a comparison
level indicating weak (sample PCR band intensity weaker
than genomic DNA band) or strong (sample PCR band
intensity similar or stronger than genomic DNA band) EGFR
expression in the samples.
Following PCR, identical aliquots (5 l ) of reaction
products were electrophoretically separated on 2% agarose
gels and PCR products were visualized by ethidium bromide
staining. Densitometric analysis of the bands was performed
using PCR-analysis software ( Image Master VDS; Pharma-
cia, Freiburg, Germany).
Results
Results of Interphase FISH for Chromosome 7
Eight melanocytic nevi, 18 primary melanomas, 41
melanoma metastases and seven control samples were
analyzed for their chromosome 7 karyotype by interphase
FISH using a DNA probe specific for centromere of
chromosome 7. Aside from nuclei with normal chromosome
7 karyotype we observed different fractions of nuclei with
trisomy 7 as well as nuclei with monosomy 7 and such with
four or more signals for chromosome 7 in all examined
melanoma specimen (Table 1). The number of hybridization
spots per nucleus ranged from 0 to 8. The average fraction of
nuclei with normal karyotypic status for chromosome 7 (two
fluorescent signals) was 83.1% in control samples and
82.3% in benign nevi, respectively. In primary melanomas
only 75.0% of nuclei were normal declining to melanoma
metastases, where only an average of 51.3% of cell nuclei
showed normal chromosome 7 karyotype (Figure 1 ). Nuclei
with monosomy 7 were observed in approximately equal
amounts in controls and nevi (mean value 10.8% and 11.3%,
respectively), less in primary melanomas (8.6%), and least
in metastases (6.4%). However nuclei with trisomy 7 were
found much more frequently in metastases (mean value
25.3%) than in primary melanomas (8.2%), nevi (3.7%),
and control samples (3.4%). The distributions of the mean
fraction of nuclei with a certain number of FISH signals in
primary melanomas and melanoma metastases (Figure 1 )
are significantly different (P=.0001, Kolmogorov-Smirnov
exact test ).
There was no correlation of FISH results with the standard
pathologic prognostic factors Breslow thickness, Clark level,
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Figure 1. Mean fraction of nuclei (% ) with a certain number of FISH signals
for chromosome 7 in interphase nuclei of benign and malignant tissue
samples.
Table 2. Clinical Data of Primary Malignant Melanomas and Chromosome 7 FISH Results, Sorted on Clark Level.
Diagnosis Case no. Localization Breslow Clark Metastasis Signals per nucleus (%)
thickness (mm) level 0 1 2 3 4 5 6 7 8 >5
SSM 474 hand <0,75 I neg 1.0 10.0 81.0 8.0 0.0 0.0 0.0 0.0
LMM 289 head 0.3 II ND 0.0 11.8 82.4 4.9 1.0 0.0 0.0 0.0
SSM 236 thigh 1.04 II neg 2.0 13.0 70.0 8.0 4.0 0.0 0.0 3.0
SSM 352 back 1.04 II neg 1.0 11.0 80.0 6.0 1.0 1.0 0.0 0.0
MM 268 back 0.7 III ND 2.0 6.0 77.0 6.0 8.0 0.0 1.0 1.0
NMM 209 shoulder 2.1 III ND 0.0 16.4 76.2 6.6 0.8 0.0 0.0 0.0
SSM 315 back 0.38 III ND 1.0 5.0 89.0 4.0 1.0 0.0 0.0 0.0
MM 363 abdomen 1.69 IV pos 0.0 1.0 77.0 12.0 5.0 4.0 1.0 1.0
NMM 267 back 11 IV ND 0.0 4.0 70.0 10.0 1.0 6.0 9.0 9.0
NMM 291 lower leg 5.25 IV pos 0.9 16.8 76.6 5.6 0.0 0.0 0.0 0.0
NMM 293 lower leg 5.25 IV pos 2.0 5.0 84.0 7.0 1.0 1.0 0.0 0.0
SSM 250 ear 5 IV pos 0.0 5.0 83.0 7.0 5.0 0.0 0.0 0.0
LMM 295 ND ND ND ND 1.0 2.0 25.0 13.0 22.0 19.0 17.0 1.0 18.0
MM 210 ND ND ND ND 0.0 8.8 49.0 32.4 6.9 ND ND 2.9
MM 308 ND ND ND ND 2.0 4.0 91.0 2.0 1.0 0.0 0.0 0.0
NMM 290 ND ND ND ND 1.0 17.0 79.0 2.0 1.0 0.0 0.0 0.0
SSM 211 back 0.8 ND ND 0.0 7.7 81.7 7.7 1.9 0.0 0.0 1.0
SSM 307 ND ND ND ND 2.0 10.0 78.0 6.0 4.0 0.0 0.0 0.0
Mean value 0.9 8.6 75.0 8.2 3.6 1.8 1.6 2.0
Standard deviation 0.8 4.9 14.9 6.5 5.0 4.6 4.4 4.4
neg, negative. pos, positive. ND: not determined.
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and metastasis in cases of primary melanomas where
clinical data was available (Table 2).
Figure 2 illustrates a case where a melanoma metastasis
(case 311) and the clinically unaffected skin adjacent to the
metastasis (case 312) from the same patient were available
for FISH investigation. The fraction of cell nuclei with normal
chromosome 7 karyotype increased from 39% in the meta-
stasis to 83% in the adjacent skin, whereas the fraction of
nuclei with trisomy 7 decreased from 36% to 4%. In this case
no nuclei with four chromosomes 7 were detectable in the
adjacent tissue but 20% of metastatic nuclei showed this
tetrasomy 7.
Based on previously published results [27] chromosome 7
number in tumor cells was regarded as an essential
chromosomal component of the tumor if 20% or more of
nuclei showed a certain number of copies. Of the investigated
metastases, 19/41 (46.3%) showed trisomy 7 in at least 20%
of nuclei, whereas only 1/18 (5.6%) primary melanomas,
and none of the nevi and controls fitted this criteria.
Compared with primary melanomas (3.6%), nevi (0.9%),
and controls (0.6%), cell nuclei with four chromosomes 7
appearedmost frequently in metastatic cases (8.0%). Seven
of 41 metastases (17.1%) showed four chromosomes 7 in at
least 20% of nuclei, compared to only 1/18 (5.6%) primary
melanomas and none of the nevi (n=8) and controls (n=7).
Five chromosomes 7 in more than 20% of nuclei were
found in 5/41 metastases (12.2%) but in none of the 18
primary melanomas. No cell nuclei with five chromosomes 7
were scored in nevi and control samples. Two metastatic
samples (cases 292 and 416) showed even more than 20%
of nuclei with six signals for chromosome 7, whereas none of
the primary melanomas, nevi and controls fitted this criteria.
Results differed among the individual cases. Looking at
single cases of primary malignant melanomas the highest
fractions of nuclei with three or four chromosomes 7 were
32.4% (case 210) and 22% (case 295), respectively. In
single metastatic cases, we detected up to 86% of nuclei with
trisomy 7 (case 475, Figure 3 ) and up to 40% of nuclei with
four (case 420), 44% with five (case 266) and 22% (case
416, Figure 4 ) with six chromosomes 7. Metastatic case 420
even showed 90% of nuclei with more than two chromo-
somes 7.
To sum up, we detected nuclei with more than two
hybridization signals for chromosome 7 in nevi and control
cases in less than 5% (mean values), in primary melanomas
in about 15%, but in metastases an average of more than
41% of nuclei revealed more than two chromosomes 7
(Table 1). The observed difference between primary
melanomas and metastases is statistically significant
(P=.0001).
Additionally, we performed interphase FISH for chromo-
some 7 on nuclei derived from primary cell cultures of two
nevi, one primary melanoma, and three melanoma meta-
stases. In nuclei of the two cultured nevi, we found a similar
fraction of 82% of nuclei with two chromosomes 7 and about
7% and 8% with three or one signal(s). In the cultured cells
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Figure 2. Fraction of nuclei (% ) with a certain number of chromosomes 7 in
samples of melanoma metastasis and adjacent unaffected skin from the same
patient.
Figure 3. Interphase nuclei of a melanoma metastasis ( case 475 ) showing
two to four FISH signals for chromosome 7.
Figure 4. Two interphase nuclei of a melanoma metastasis ( case 416 ) with
five or six FISH signals for chromosome 7.
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of the primary melanoma, 84% of nuclei showed a normal
chromosome 7 karyotype and no nuclei with additional
chromosome 7 copies were found. One of the three cultured
melanoma metastases showed a relatively inconspicuous
chromosome 7 karyotype (88% nuclei with two signals, 8%
three signals), whereas the other two cultured metastatic
cases owned 84% and 92% nuclei with trisomy 7, respec-
tively.
Results of RT-PCR analysis of EGFR Gene Expression
A total of 105 tissue samples from patients with
melanocytic nevi, cutaneous malignant melanomas, and
normal skin samples were studied. Clinicopathologic data
concerning tumor type and, in the case of primary
melanomas, tumor thickness were obtained. With regard to
tumor thickness of primary melanomas, nodular malignant
melanomas and superficial spreading melanomas were
analyzed separately, because the average tumor thickness
at time of diagnosis in general is higher in nodular malignant
melanoma than in superficial spreading melanoma.
Each sample was investigated for EGFR and GAPDH
expression. Figure 5 shows a representative example of
EGFR RT-PCR products of different investigated tissue
types and the classification in weak and strong expression
relative to the PCR band intensity of genomic DNA.
Twenty-seven percent (6 /22) of primary superficial
spreading melanomas and even fewer nodular malignant
melanomas (21%, 4/19) showed mostly strong (18% and
16%, respectively ) EGFR RNA expression (Figure 6 ).
EGFR -expressing primary melanomas had a lower tumor
thickness than EGFR -negative melanomas. Nodular malig-
nant melanomas expressing EGFR had a mean tumor
thickness of 1.6 mm in contrast to 3.7 mm in EGFR -negative
tumors. Similar results were found in superficial spreading
melanomas: 0.7 mm in EGFR -positive versus 0.9 mm in
EGFR -negative melanomas. One of two acrolentiginous
melanomas, 2/2 lentigo malignant melanomas, 1/2 mela-
nomas on nevus and 1/2 locoregional cutaneous melanoma
metastases were EGFR positive.
EGFR expression was undetectable in 63% of normal skin
tissue (10/16). The highest EGFR expression frequency
was found in melanoma metastases (57%, 8/14) followed
by nevi (50%, 14/28). However, 43% of all examined nevi
(corresponds to 86% of EGFR -positive nevi ) expressed
EGFR weakly, whereas only 7% (corresponds to 14% of
EGFR -positive nevi ) showed a strong EGFR expression
level (Figure 6 ). This is in contrast to the findings in
melanoma metastases, where 29% of all investigated cases
showed strong expression (corresponds to 50% of EGFR -
positive metastases). Thus, we found the highest frequency
of strong EGFR expression by far in melanoma metastases,
compared to all other investigated tissues.
Figure 5. Representative picture of agarose gel ( 2%) electrophoresis of EGFR RT-PCR products (product size: 398 bp ).
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Discussion
The highest frequency of strong EGFR gene expression was
detected in melanoma metastases. Overexpression of
EGFR due to gene amplification has been reported in late-
stage melanomas [28]. Our findings in metastases on RNA
level are in accordance with published data obtained on
protein level by immunohistochemical staining, where the
highest fraction of positive stained samples was found in
melanoma metastases, too [29]. Because the oncogenic
effect of RTKs of subclass I derives from overexpression
rather than mutation, strong expression of EGFR is probably
the point of interest in melanoma. Thus, if we concentrate on
the fraction of strong EGFR expression, primary melanomas
lie between nevi and metastases (Figure 6 ). Thus, our
results support the hypothesis of an increasing EGFR
expression in human melanocytic tumor progression as
postulated by de Wit et al. [29]. The relatively high rate of
normal skin samples exhibiting strong EGFR gene expres-
sion (Figure 6 ) might be explained by the biological nature of
skin as a tissue composed of different cell types. Whereas
nevi and melanomas are thought to consist of cells with a
melanocytic origin, melanocytes are only a small fraction in
normal skin besides fibroblasts, keratinocytes, and other cell
types. Normal human skin keratinocytes are well known to
express EGFR [30,31], and EGFR expression seems to play
an important role in the growth and differentiation of named
cells [32]. This might probably be the reason for the relatively
high EGFR gene expression rate observed in normal skin
whereas it is still below that observed in melanoma
metastases.
Using FISH, we detected the highest fraction of nuclei with
chromosome 7 aneusomy in melanomametastases. Only an
average of 51% of the examined nuclei of these samples
showed normal chromosome 7 karyotype whereas more
than 41% exhibited more than two chromosomes 7. The
detected difference between this distribution and that
observed in primary melanomas is statistically significant
(P=.0001). This might point to an important role of
aneusomy 7 rather in the metastatic progression than in
the pathogenesis of the disease.
Aneusomy 7 has often been found in other malignancies,
for example in prostate cancer. Brown et al. [33] observed
gain of chromosome 7 in 20% of touch preparations of
prostate carcinoma samples by FISH. Barranco et al. [34]
found chromosome 7 and/or chromosome 8 aneusomy in all
investigated aneuploid prostate cancer samples. They found
trisomy 7 to be the most frequent alteration present in 56% of
aneuploid tumors. Takahashi et al. [35] detected gain of
chromosome 7 in 76% of aneuploid prostate carcinomas. In
primary cutaneous melanomas chromosome 7 copy number
gain was found in 50% (n=32) of cases by comparative
genomic hybridization [36]. The authors speculate that gain
of chromosome 7 occurs late in melanoma progression.
Matsuta et al. [27] detected copy number gain of chromo-
some 7 in 40.9% of primary and metastatic melanomas by
FISH. Taking our results and the mentioned publications into
account, aneusomy of chromosome 7 might play an
important role in metastasis of malignant melanomas. This
might be due to an increased copy number of the EGFR
gene, which is located on chromosome 7p12.3-p12.1 and
which we found most frequently expressed in melanoma
metastases.
There are other genes on chromosome 7 that play a role
in human malignancies and might be also involved in
malignant melanoma. B-raf proto-oncogene is located on
7q34 [37]. The gene for platelet -derived growth factor alpha
(PDGF-A ) maps to 7p22 [38]. PDGF-A is expressed in
primary and malignant melanoma but not in normal skin [39],
and might function as an autocrine growth factor as well as
an angiogenesis factor in tumor development. Plasminogen
activator inhibitor type 1 (PAI-1 ) gene is located in region
7q21.3-q22 and was found to be expressed in highly
invasive metastatic human melanoma cell lines but not in
those lacking this characteristic [40]. This suggests a
putative role of PAI-1 expression in metastasis of malignant
melanoma. Another important cancer- related gene is the
MET proto-oncogene on 7q31, encoding for a membrane
receptor protein with, like EGFR, tyrosine–protein kinase
activity. MET gene was shown to be overexpressed in
sporadic papillary renal cell carcinoma where trisomy 7 is the
most frequently observed cytogenetic abnormality [41],
suggesting that a gene (or genes) located on chromosome
7 plays a role in the pathogenesis of this neoplasia. Wullich et
al. [42] found the EGFR gene and the MET gene
independently amplified in human glioma, a tumor where
gains of chromosome 7 are frequent [43]. In malignant
melanoma, MET gene was shown to be expressed at a
significant level at late stages of melanoma progression
(metastatic lesions) [44]. The localization of a variety of
additional cancer - related genes together with EGFR on
chromosome 7 might suggest a possible overexpression of
these genes in melanoma metastases through increased
gene copy numbers through the observed polysomy 7.
Whether the discovered interdependence of polysomy 7 and
metastasis is causative, correlative or consequential is a
fascinating question from a biological viewpoint, which is
going to be addressed in a consecutive study.
Our FISH results in percent are mean values and
standard deviations for the mean fraction of nuclei with a
certain number of FISH signals for chromosome 7 are quite
high (Table 1). This is due to the partly big differences
concerning chromosome 7 karyotype among the single
metastatic cases. The panel ranges from metastases that
appeared to have normal chromosome 7 karyotypes in
almost all investigated nuclei to cases where about 90% of
nuclei owned more than two chromosomes 7. There are two
possibilities to explain these differences. Firstly, if we
postulate that tumor cells differ in their karyotypes from
normal cells, the observed differences could be due to the
heterogeneity of tissue samples leading to ‘‘contamination’’
of touch preparations with nontumorous cells. In these
cases, the fraction of nuclei with aneuploidy or aneusomy
might depend on the percentage of tumor tissue in the touch
preparations and might differ among the single cases.
Secondly, the differences between metastases might be
well founded in the possibility that there are tumors that have
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a relevant fraction of cells with an aberrant chromosome 7
karyotype and others that consist mainly of inconspicuous
cells, as far as chromosome 7 is concerned. Our findings in
nuclei of short - term primary cultures, where identity of cells
as tumor cells was clear and where we found metastases
with and without numerical aberrations of chromosome 7,
point to the latter hypothesis. Taking this into account, there
could be a principal difference in proliferative and dissem-
inating potential of metastases with differing chromosome 7
copy numbers. This hypothesis, though accounting a
controlled prospective trial, may be the most interesting to
follow.
The FISH results observed in cells derived from short -
term primary cultures are comparable to those obtained from
touch preparations. In future FISH investigations, short - term
primary culture of sample cells will be the method of choice
whenever possible, because selective effects are minimal
and identity of cells is much more easy to determine. The
interesting findings on the difference of aneusomy 7 rates in
safety margins and melanomas or melanoma metastases
might help to identify the necessary resection margin by
means of this cytogenetic approach.
Gain and aberrations of chromosome 7 have been
described to correlate with worse prognosis in various
neoplasias. In prostate cancer gain of chromosome 7 was
strongly associated with advanced tumor stages [35] and
alterations of chromosome 7 were observed in 96% of
patients with poor prognosis [45]. Additionally, trisomy 7 and
monosomy 8 were significantly associated with poor
prognosis in prostate cancer [34]. In a chromosome banding
study on tumor biopsies from patients with metastatic
melanoma, Trent et al. [46] observed that melanoma
patients with structural abnormalities of chromosome 7 or
11 had a significantly shorter survival time than patients
without these abnormalities. These observations and our
findings certainly warrant further studies on the importance
of increased copy numbers or aberrations of chromosome 7
as a prognostic parameter also for melanoma.
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